Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

2.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.2K
The Two-State Receptor Model01:29

The Two-State Receptor Model

2.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.8K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

13.8K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.8K
Non-gated Ion Channels01:24

Non-gated Ion Channels

7.2K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
7.2K
GPCR Desensitization01:12

GPCR Desensitization

6.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seal and fish oils partially counteract inflammation and modulate endocannabinoidome lipid and oxylipin alterations in DSS-induced colitis.

Scientific reports·2026
Same author

Computational Studies toward the Identification of CB2R-M1R Dual Modulators.

ACS omega·2026
Same author

Structural and functional dissection of the WH2/DAD motif of INF2, a formin linked to human inherited degenerative disorders.

The FEBS journal·2025
Same author

Impact of Oral Cannabinoids on the Endocannabinoidome and Gut Microbiome in People with HIV on Antiretroviral Therapy (CTN PT028 Pilot Clinical Trial).

Cannabis and cannabinoid research·2025
Same author

Inherited retinal diseases in Kentucky: diagnostic yield, gene variants, and novel mutations in a U.S. population.

BMC medical genomics·2025
Same author

Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer.

Biomolecules·2024

Related Experiment Video

Updated: Sep 30, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K

Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators.

Paula Morales1, Chanté Muller2, Nadine Jagerovic1

  • 1Medicinal Chemistry Institute, Spanish National Research Council, Madrid, Spain.

Frontiers in Molecular Biosciences
|March 14, 2022
PubMed
Summary

This study identifies potential drug candidates targeting both CB2 and TRPV1 receptors for neurological disorders. This dual-target approach may offer effective, non-psychoactive treatments for conditions like pain and neurodegeneration.

Keywords:
CB2TRPV1cannabinoidsdual ligandsionotropic receptorsmultitargeting

More Related Videos

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

Related Experiment Videos

Last Updated: Sep 30, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Metabotropic (CBRs) and ionotropic cannabinoid receptors (ICRs) are implicated in neurological disorders.
  • Canonical CB1 and CB2 receptors play significant roles in neuropathology.
  • Selective CB2 targeting offers therapeutic advantages over CB1 due to reduced psychoactive effects.

Purpose of the Study:

  • To identify novel chemotypes with a dual CB2 and TRPV1 receptor activity profile.
  • To explore a polypharmacological strategy for treating neurological conditions.
  • To investigate potential therapeutic applications in analgesia and neuroprotection.

Main Methods:

  • Rationalized key structural features for CB2 and TRPV1 receptor activation.
  • Performed virtual screening of curated chemical libraries against both targets.
  • Identified potential dual CB2/TRPV1 modulators.

Main Results:

  • Identified specific chemotypes exhibiting potential for dual CB2/TRPV1 targeting.
  • Demonstrated the feasibility of a polypharmacological approach for neurological disorders.
  • Provided a foundation for further drug development in this area.

Conclusions:

  • Dual targeting of CB2 and TRPV1 receptors presents a promising therapeutic strategy.
  • This approach may lead to novel treatments for neurological diseases with improved safety profiles.
  • Further research is warranted to validate and develop these identified chemotypes.